The regulations provide guidance to employers and sponsors regarding the definition of a grandfathered health plan, as well as the changes that may and may not be made.
In June, the Departments of Health and Human Services, Labor and Treasury jointly issued interim final rules providing guidance on grandfathered health plans under the Patient Protection and Affordable Care Act, as modified by the Health Care and Education Reconciliation Act. The regulations provide guidance to employers and sponsors regarding the definition of a grandfathered health plan, as well as the changes that may and may not be made.
Specifically, (among other exemptions) grandfathered health plans: do not have to maintain an appeals process that includes an external review; are not subject to the requirements to provide specified preventive care without any cost sharing to participants; and are not subject to certain nondiscrimination rules.
The interim rules specify a number of changes which would result in the grandfathered health plan losing its status. These include, but are not limited to: entering into a new policy, certificate, or contract of insurance with the plan's insurance issuer; changing the plan to eliminate all or substantially all benefits to diagnose or treat a particular condition; increasing any percentage cost-sharing requirement; and increasing a fixed-amount cost-sharing requirement, other than a copayment (a deductible, for example), if the total percentage increase in the cost-sharing requirement exceeds the "maximum percentage increase."
Changes that will not cause a health plan to lose its grandfather status include: changes to comply with federal or state law; changes to increase benefits; and changes to a plan's third party administrator.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
More Results for Nerandomilast Reported by BI, This Time for Progressive Pulmonary Fibrosis
February 15th 2025Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B inhibitor as a treatment for progressive pulmonary fibrosis.
Read More